Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...

Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.

Under the terms of the agreement, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Skip to main content Exclusive news, data and analytics for financial market professionals Learn ...

Eli Lilly and Company says it will acquire the gene therapy start-up Verve Therapeutics for $1.3 billion. Verve’s lead drug candidate, VERVE-102, turns off the PCSK9 gene in the liver to reduce ...

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right worth up to $3 ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...